Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Clinicians shaking hands
Sonia Houghton, CEO at Cryoniss, and Nick Ash, CEO at Biofortuna.
iStock, PeopleImages

Biofortuna Acquires Biological Sample Storage Company Cryoniss

Deal centers on temperature-controlled services

Published:May 13, 2024
|1 min read
Register for free to listen to this article
Listen with Speechify

DEESIDE, WALES—Biofortuna Ltd., a specialist laboratory services and contract development and manufacturing organization, has completed the acquisition of Cryoniss Ltd., underlining Biofortuna’s commitment to support life-changing research and development across the global biotech and life sciences sector.

The acquisition of Cryoniss brings expertise and infrastructure in temperature-controlled biological sample storage, strengthening Biofortuna’s existing stability storage capability and accelerating the growth of its controlled-environment storage offering.

Cryoniss specializes in sample storage and biorepository solutions at ultra-low and cryogenic conditions for long-term storage of biological samples in the global life sciences sector, research institutions, and governmental agencies. Applications include academic research, therapeutic drug discovery, and diagnostic test development. 

“Cryoniss is a perfect fit with our existing controlled- environment storage and cell line services business,” said Dr. Nick Ash, CEO at Biofortuna. “With customers increasingly looking for single-site provision of sample storage and analytical services, Biofortuna is now perfectly positioned to deliver a fully integrated, end-to-end service.”

Sonia Houghton, CEO at Cryoniss, added, “The acquisition by Biofortuna presents a host of new opportunities. It will allow us to showcase our expert temperature-controlled services to a much wider audience across the life sciences and biotech sectors and enable our customers to access our highly accredited services quickly and efficiently.”

Biofortuna provides genomic services, custom assay development, and contract manufacturing solutions to global customers in health care, biotech, and academia.

- This press release was originally published on the Biofortuna website.